Action on Hearing Loss Logo
    Total results:
    Search
      Total results:

      Protecting the hearing of premature babies – how our funding is helping

      In 2016, we funded Professor William Newman at the University of Manchester to develop a quick test for a specific genetic mutation that increases someone’s risk of losing their hearing, if they have to take certain life-saving antibiotics. He used the results to obtain a further £900,000 from other funders to develop the test so that it can be used in clinics to protect the hearing of premature babies. Tracey Pollard, from our Biomedical Research team, tells us more.

      By: Tracey Pollard | 12 July 2018

      A certain type of antibiotic (the aminoglycosides, such as gentamicin, kanamycin and tobramycin), are used widely across the world to treat life-threatening bacterial infections, including tuberculosis. These drugs have a downside, however – some people treated with them develop irreversible, and often profound, hearing loss. As a result, they are used sparingly in high-income countries, often as a treatment of last resort – for example, to combat serious chest infections or sepsis. They are also used to protect premature babies from infections that their under-developed immune system cannot cope with. Aminoglycosides are effective against a wide range of bacteria, so they are well-suited to this, despite the associated risk of hearing loss.

      Around 1 in 500 people have a mutation (change in the DNA sequence) in a specific gene called MT-RNR1. The mutation is known as m.1555A>G. This mutation is strongly linked to the development of profound hearing loss after even a single dose of aminoglycoside. Children with cystic fibrosis are often tested for this mutation, because at some point in their care, they will require treatment with an aminoglycoside. Knowing if they have the mutation helps doctors to minimise the risks to the children’s hearing. However, the testing isn’t appropriate for premature babies – they often have to be given antibiotics urgently, and doctors can’t wait the three days it currently takes to get the test results.

       

      Developing a ‘point of care’ test for m.1555A>G

      We awarded a £5,000 Flexi Grant to Professor William Newman, based at the University of Manchester, to develop a genetic test for the m.1555A>G mutation that could detect it quickly, and ultimately allow doctors to make the best decisions for premature babies who need antibiotic treatment. Professor Newman collaborated with Genedrive, a Manchester-based company, to use their technology to develop a ‘point of care’ testing device for m.1555A>G. A point of care test is one that can be carried out as someone is being treated in a clinic, or, if they’re in hospital, at their bedside. The goal of these tests is to provide accurate results within a very short time (often minutes), thus speeding up diagnosis and treatment.

      With the funding we gave them, the researchers were able to successfully design a device which could test for the mutation in a saliva sample, and generate an accurate result (whether someone has the mutation or not) within 35 minutes. Based on these results, they applied to the National Institute for Health Research (NIHR), the research funding arm of the NHS, for an i4i (Invention for Innovation) grant to develop their new technology further. Their application was successful, with the NIHR granting them £900,000 to continue their work. With these funds, they hope to further develop their technology to make it suitable for routine clinical use, and to gain CE certification for their device (to show that it conforms with health, safety and environmental protection standards required for products sold within the European Economic Area). They also plan to undertake feasibility and acceptance studies to show that the test can be used clinically, and that people are willing to take the test or allow their baby to take the test. This work is needed before the test can be rolled out for clinical use across the NHS.

      What does this mean?

      This test could be used to test all premature babies who need antibiotic treatment for whether they have the m.1555A.G mutation. If they have the mutation, then doctors can treat them with different antibiotics, to help protect their hearing. Introducing this test could help to reduce the number of premature babies in the UK who lose their hearing after being treated with aminoglycosides each year (estimated to be, on average, 1 case per neonatal unit/year). The researchers hope that their test, once they have developed it so that it is high enough quality to be used in the clinic, should cost much less than standard testing.

      This grant could ultimately lead to a transformation of clinical practice in the UK (and worldwide) to avoid preventable antibiotic-induced hearing loss. It is a great example of how a small amount of funding from us can turn into a significant investment from other, larger research funders, giving projects the kick-start they need to bring real benefit to people.

      Find out more

      We depend on your donations so we can fund the best hearing and tinnitus research around the world. Donate today and help us continue our vital work into hearing treatments, so that people can live life to the full again.

      You can find out more about the research we’re funding in our biomedical research (https://www.actiononhearingloss.org.uk/finding-cures/our-biomedical-research/) section.

      If you’re interested in finding out more about our research, sign up to receive our Soundbite (https://www.actiononhearingloss.org.uk/finding-cures/our-biomedical-research/research-news/) e-newsletter. It’s a monthly email, filled with the latest news about hearing and tinnitus research, and hearing technology.

      Recent Posts

      International Symposium on Inner Ear Therapeutics

      Earlier this month Action on Hearing Loss joined scientists, pharmaceutical companies and clinicians from around the world in Hanover, Germany, to discuss the latest developments in treatments for inner ear-related diseases, including hearing loss and tinnitus.

      By: Cláudia Gonçalves
      19 November 2019

      Tech ideas to help raise awareness of hearing loss

      For the last couple of years, Microsoft UK has hosted an Ideas Generator event for charities. It’s a chance to explore how charities can harness the latest technology to provide real-world solutions. This year, the Microsoft team chose Action on Hearing Loss to attend along with four other charities.

      By: Kevin Taylor
      14 November 2019

      How Akouos Therapeutics is working to develop genetic therapies for hearing loss

      Ακούω is a Greek word that means to listen. Akouos Therapeutics (pronounced ah KOO ohs) is a biotechnology company based in Boston, USA. It was formed in 2016 with the goal of applying precision genetic medicine to conditions that cause hearing loss. A key step in the development of such treatments underlies the choice of the company’s name.

      By: Jim McLaughlin, Akouos Therapeutics
      14 November 2019

      Hearing Health by Apple

      Hearing loss caused by excessively loud music and audio from personal listening devices is an increasing problem. In the latest version of their Health app, Apple are introducing new features to tackle the issue. They will be available as part of their iOS13.1 software update.

      By: Jesal Vishnuram
      11 October 2019

      Recent Posts

      International Symposium on Inner Ear Therapeutics

      Earlier this month Action on Hearing Loss joined scientists, pharmaceutical companies and clinicians from around the world in Hanover, Germany, to discuss the latest developments in treatments for inner ear-related diseases, including hearing loss and tinnitus.

      By: Cláudia Gonçalves
      19 November 2019

      Tech ideas to help raise awareness of hearing loss

      For the last couple of years, Microsoft UK has hosted an Ideas Generator event for charities. It’s a chance to explore how charities can harness the latest technology to provide real-world solutions. This year, the Microsoft team chose Action on Hearing Loss to attend along with four other charities.

      By: Kevin Taylor
      14 November 2019

      How Akouos Therapeutics is working to develop genetic therapies for hearing loss

      Ακούω is a Greek word that means to listen. Akouos Therapeutics (pronounced ah KOO ohs) is a biotechnology company based in Boston, USA. It was formed in 2016 with the goal of applying precision genetic medicine to conditions that cause hearing loss. A key step in the development of such treatments underlies the choice of the company’s name.

      By: Jim McLaughlin, Akouos Therapeutics
      14 November 2019

      Hearing Health by Apple

      Hearing loss caused by excessively loud music and audio from personal listening devices is an increasing problem. In the latest version of their Health app, Apple are introducing new features to tackle the issue. They will be available as part of their iOS13.1 software update.

      By: Jesal Vishnuram
      11 October 2019

      More like this

      We're really proud of everyone who's a part of Action on Hearing Loss, and hope you'll feel inspired to become a part of our community.​

      We campaign for changes that make life better for people who are confronting deafness, tinnitus and hearing loss.

      Our ears are our organs of hearing and balance. They have three parts: the outer, middle and inner ear.